Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH)'s subsidiary Guangzhou Pharmaceutical plans to increase capital and expand shares to introduce strategic investors, raising no more than RMB6 billion.

Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that its controlling subsidiary Guangzhou Pharmaceutical Co., Ltd. ("Guangzhou Pharmaceutical") plans to introduce strategic investors through a public listing on the Guangzhou Equity Exchange and implement a targeted share issuance, planning to solicit no more than 15 investors, with an issue price of no less than RMB3.46 per share, a targeted issuance of no more than 1.734 billion shares, and a fundraising scale of no more than RMB6 billion. According to the provisions of Guangzhou Pharmaceutical's articles of association, the company does not enjoy a preemptive right in this capital increase and share expansion. After the completion of this capital increase and share expansion, the company is expected to hold no less than 53.23% of the equity of Guangzhou Pharmaceutical. The company will remain the controlling shareholder of Guangzhou Pharmaceutical, which will not cause a change in the scope of the company's consolidated financial statements and will not have a material adverse impact on the company's production and operations.